Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 123-128

  Yoon, Seonghae ^a   Lee, Howard ^b   Kim, Tae Eeun ^a   Lee, SeungHwan ^a   Chee, Dong Hyun ^c   Cho, Joo Youn ^a   Yu, Kyung Sang ^a   Jang, In Jin ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c ABBVIE INC   (United States)

Author keywords

Bioavailability; Extended release; Immediate release; Itopride; Pharmacokinetics

Indexed keywords

ITOPRIDE; BENZAMIDE DERIVATIVE; BENZYL DERIVATIVE; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EAR DISEASE; ETHNIC GROUP; FAINTNESS; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMEDIATE RELEASE FORMULATION; KOREAN; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE RIGIDITY; MUSCLE TIGHTNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; STEADY STATE; SUSTAINED RELEASE FORMULATION; DELAYED RELEASE FORMULATION; MEDICINAL CHEMISTRY; MIDDLE AGED; YOUNG ADULT;

ADULT; BENZAMIDES; BENZYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84892609452     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S53027     Document Type: Article

References (15)

1. Iwanaga Y, Kimura T, Miyashita N, et al. Characterization of acetylcholinesterase-inhibition by itopride. Jpn J Pharmacol. 1994;66(3): 317-322. Available from: http://dx.doi.org/10.1254/jjp.66.317. Accessed December 3, 2013.
2. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol. 2005;11(27):4210-4214.
3. Katagiri F, Shiga T, Inoue S, Sato Y, Itoh H, Takeyama M. Effects of itopride hydrochloride on plasma gut-regulatory peptide and stress-related hormone levels in healthy human subjects. Pharmacology. 2006;77(3):115-121.
4. Kreutzkamp B. [Functional dyspepsia. Itopride improves symptoms]. Med Monatsschr Pharm. 2006;29(10):387-388. German.
5. Sun J, Yuan YZ, Holtmann G. Itopride in the treatment of functional dyspepsia in chinese patients: a prospective, multicentre, post-marketing observational study. Clin Drug Investig. 2011;31(12):865-875.
6. Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57(6):740-746.
7. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354(8):832-840.
8. Nakajima M, Uematsu T, Nakajima S, Nagata O, Yamaguchi T. Phase 1 study of HSR-803. Jpn Pharmacol Ther. 1993;21(11):4157-4173.
9. Mushiroda T, Douya R, Takahara E, Nagata O. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos. 2000;28(10): 1231-1237.
10. Demol P, Ruoff HJ, Weihrauch TR. Rational pharmacotherapy of gastrointestinal motility disorders. Eur J Pediatr. 1989;148(6):489-495.
11. Keith A Sharkey, Wallace JL. Treatment of disorders of bowel motility and water flux; anti-emetics; agents used in biliary and pancreatic disease. In: Brunton LL, Blumenthal DK, Murri N, Dandan RH, Knollmann BC. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York, NY, USA: The McGraw-Hill Companies, Inc; 2011.
12. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379-390.
13. Malinowski H, Marroum P, Uppoor VR, et al. Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol. 1997;423:269-288.
14. Guidance on Evaluation of the Safety and Efficacy of Medicinal Products. Republic of Korea: The Korean Food and Drug Administration; 2013.
15. Welling PG. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm. 1977;5(4):291-334.